:Blarcamesine    (DrugBank: Blarcamesine)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
156レット症候群1

156. レット症候群 [臨床試験数:36,薬物数:49(DrugBank:19),標的遺伝子数:77,標的パスウェイ数:112
Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 36 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004345-32-GB26/05/202007/02/2020The use of ANAVEX2-73 as a new therapeutic treatment for Patients with Rett SyndromeA Double-Blind, Randomised, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients with Rett Syndrome - The Safety and Efficacy of ANAVEX2-73 in Patients with Rett Syndrome Rett Syndrome
MedDRA version: 20.0Level: PTClassification code 10077709Term: Rett syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: ANAVEX2-73
INN or Proposed INN: ANAVEX2-73 (blarcamesine)
Other descriptive name: ANA001XHCl (Syntagon) or VEXA-04 (Patheon)
Anavex Germany GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
30Phase 2Australia;United Kingdom